Yahoo Finance

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on the positive GRIPHON Study Results today, on Monday, 16 June 2014, at 14.00 CEST / 13.00 BST / 08.00 a.m. EDT.

The company announced today that selexipag met the primary endpoint in the pivotal Phase III GRIPHON outcome in patients with pulmonary arterial hypertension.

Actelion will present the top-line results and be available for Q&A.

Management will be represented by:

• Jean-Paul Clozel (Chief Executive Officer)

• Guy Braunstein (Head of Global Clinical Development)

• Andrew Weiss (Head Investor Relations & Corporate Communications)

Date/Time:

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Participant`s mode:

Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

Participant`s mode:

Listen only

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

For further information please contact:

Andrew Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

Invitation PDF

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
HUG#1793158